TGFB1 and Hepatic fibrosis: In experimental models of hepatic fibrosis, angiotensin-converting enzyme inhibitors (ACE-I) and/or Ang II type 1 receptor (AT1) blocker significantly inhibited the upregulation of TGF-β expression and HSC activation12, 13.